{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:37:13Z","timestamp":1788561433569,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T00:00:00Z","timestamp":1358553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00296-013-2674-7","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T09:14:51Z","timestamp":1358500491000},"page":"1845-1853","source":"Crossref","is-referenced-by-count":18,"title":["Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats"],"prefix":"10.1007","volume":"33","author":[{"given":"Yao","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong-zhu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,19]]},"reference":[{"key":"2674_CR1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrd1109","volume":"2","author":"JS Smolen","year":"2003","unstructured":"Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473\u2013488","journal-title":"Nat Rev Drug Discov"},{"key":"2674_CR2","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2146\/ajhp050514","volume":"63","author":"A Gaffo","year":"2006","unstructured":"Gaffo A, Saag KG, Curtis JR (2006) Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63:2451\u20132465","journal-title":"Am J Health Syst Pharm"},{"key":"2674_CR3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/rheumatology\/kep389","volume":"49","author":"SM Rachapalli","year":"2010","unstructured":"Rachapalli SM, Williams R, Walsh DA et al (2010) First-line DMARD choice in early rheumatoid arthritis\u2014do prognostic factors play a role? Rheumatology (Oxford) 49:1267\u20131271","journal-title":"Rheumatology (Oxford)"},{"key":"2674_CR4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jbspin.2008.12.008","volume":"76","author":"P Caramaschi","year":"2009","unstructured":"Caramaschi P, Bambara LM, Pieropan S et al (2009) Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine 76:333\u2013342","journal-title":"Joint Bone Spine"},{"key":"2674_CR5","first-page":"2192","volume":"171","author":"R Christensen","year":"2009","unstructured":"Christensen R, Kristensen LE, Geborek P et al (2009) The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis: a meta-analytic literature review\u2013secondary publication. Ugeskr Laeger 171:2192\u20132194","journal-title":"Ugeskr Laeger"},{"key":"2674_CR6","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1556\/OH.2009.28681","volume":"150","author":"J Feher","year":"2009","unstructured":"Feher J, Lengyel G (2009) Effectiveness and safety of biological therapy with adalimumab. Orv Hetil 150:1215\u20131222","journal-title":"Orv Hetil"},{"key":"2674_CR7","first-page":"82","volume":"81","author":"EL Nasonov","year":"2009","unstructured":"Nasonov EL (2009) Rituximab treatment of rheumatoid arthritis: new evidence. Ter Arkh 81:82\u201391","journal-title":"Ter Arkh"},{"key":"2674_CR8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1749-6632.2009.04668.x","volume":"1173","author":"L Quartuccio","year":"2009","unstructured":"Quartuccio L, Lombardi S, Fabris M et al (2009) Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann NY Acad Sci 1173:692\u2013700","journal-title":"Ann NY Acad Sci"},{"key":"2674_CR9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-3083.2009.02296.x","volume":"70","author":"A Wiens","year":"2009","unstructured":"Wiens A, Correr CJ, Pontarolo R et al (2009) A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol 70:337\u2013344","journal-title":"Scand J Immunol"},{"key":"2674_CR10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jbspin.2008.12.007","volume":"76","author":"G Falgarone","year":"2009","unstructured":"Falgarone G, Semerano L, Rulle S, Boissier MC (2009) Targeting lymphocyte activation to treat rheumatoid arthritis. Joint Bone Spine 76:327\u2013332","journal-title":"Joint Bone Spine"},{"key":"2674_CR11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/14712590903033919","volume":"9","author":"C Bracewell","year":"2009","unstructured":"Bracewell C, Isaacs JD, Emery P, Ng WF (2009) Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 9:909\u2013919","journal-title":"Expert Opin Biol Ther"},{"key":"2674_CR12","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/ard.2010.141325","volume":"70","author":"K Muhammad","year":"2011","unstructured":"Muhammad K, Roll P, Seibold T et al (2011) Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 70:1507\u20131510","journal-title":"Ann Rheum Dis"},{"key":"2674_CR13","first-page":"678","volume":"27","author":"JA Martinez","year":"2009","unstructured":"Martinez JA, Loza E, Carmona L (2009) Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 27:678\u2013684","journal-title":"Clin Exp Rheumatol"},{"key":"2674_CR14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.berh.2004.08.009","volume":"19","author":"JS Smolen","year":"2005","unstructured":"Smolen JS, Aletaha D, Machold KP (2005) Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19:163\u2013177","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2674_CR15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","volume":"60","author":"RE Kalb","year":"2009","unstructured":"Kalb RE, Strober B, Weinstein G et al (2009) Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 60:824\u2013837","journal-title":"J Am Acad Dermatol"},{"key":"2674_CR16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1572-0241.2003.07305.x","volume":"98","author":"O Schroder","year":"2003","unstructured":"Schroder O, Stein J (2003) Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 98:530\u2013537","journal-title":"Am J Gastroenterol"},{"key":"2674_CR17","doi-asserted-by":"crossref","first-page":"R169","DOI":"10.1186\/ar2078","volume":"8","author":"A Ochaion","year":"2006","unstructured":"Ochaion A, Bar-Yehuda S, Cohn S et al (2006) Methotrexate enhances the anti-inflammatory effect of CF101 via up- regulation of the A3 adenosine receptor expression. Arthritis Res Ther 8:R169","journal-title":"Arthritis Res Ther"},{"key":"2674_CR18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.it.2003.11.003","volume":"25","author":"G Hasko","year":"2004","unstructured":"Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33\u201339","journal-title":"Trends Immunol"},{"key":"2674_CR19","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","volume":"93","author":"RI Fox","year":"1999","unstructured":"Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action of leflunomide in rheumatoid arthritis. Clin Immunol 93:198\u2013208","journal-title":"Clin Immunol"},{"key":"2674_CR20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/ard.2008.099861","volume":"68","author":"W Katchamart","year":"2009","unstructured":"Katchamart W, Trudeau J, Phumethum V et al (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68:1105\u20131112","journal-title":"Ann Rheum Dis"},{"key":"2674_CR21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0049-0172(99)80034-1","volume":"29","author":"JM Kremer","year":"1999","unstructured":"Kremer JM (1999) Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:24\u201326","journal-title":"Semin Arthritis Rheum"},{"key":"2674_CR22","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/kem279","volume":"47","author":"JAM Wessels","year":"2008","unstructured":"Wessels JAM, Huizinga TWJ, Guchelaar H-J (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47:249\u2013255","journal-title":"Rheumatology"},{"key":"2674_CR23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/ar318","volume":"3","author":"AD Cook","year":"2001","unstructured":"Cook AD, Braine EL, Campbell IK et al (2001) Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 3:293\u2013298","journal-title":"Arthritis Res"},{"key":"2674_CR24","volume-title":"Evaluation of drug activities: pharmacometrics","author":"GE Pagat","year":"1964","unstructured":"Pagat GE, Barnes JM (1964) Interspecies Dosage Conversion Scheme in Evaluation of Results and Quantitative Application in Different Species. In: Laurence DR, Bacarach AL (eds) Evaluation of drug activities: pharmacometrics. Academic press, London"},{"key":"2674_CR25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0162-3109(00)00197-1","volume":"48","author":"K Urakawa","year":"2000","unstructured":"Urakawa K, Mihara M, Suzuki T et al (2000) Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects. Immunopharmacology 48:137\u2013144","journal-title":"Immunopharmacology"},{"key":"2674_CR26","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s10067-007-0605-2","volume":"26","author":"YA Lee","year":"2007","unstructured":"Lee YA, Kim JY, Hong SJ et al (2007) Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients. Clin Rheumatol 26:2023\u20132029","journal-title":"Clin Rheumatol"},{"key":"2674_CR27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clim.2004.12.009","volume":"115","author":"A Mor","year":"2005","unstructured":"Mor A, Abramson SB, Pillinger MH (2005) The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 115:118\u2013128","journal-title":"Clin Immunol"},{"key":"2674_CR28","doi-asserted-by":"crossref","unstructured":"David AF Alison G, Rachel M et al Lundy (2010) Cell-cell Interactions in Rheumatoid Arthritis Synovium Rheum Dis Clin N Am 36: 311\u2013323","DOI":"10.1016\/j.rdc.2010.02.004"},{"key":"2674_CR29","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.yexmp.2009.06.001","volume":"87","author":"F Weiwei","year":"2009","unstructured":"Weiwei F, Weimin L, Wei L et al (2009) IL-17 induces myocardial fibrosis and enhances RANKL\/OPG and MMP\/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 87:212\u2013218","journal-title":"Exp Mol Pathol"},{"key":"2674_CR30","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3858\/emm.2008.40.2.237","volume":"40","author":"ML Cho","year":"2008","unstructured":"Cho ML, Jung YO, Kim KW et al (2008) IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp Mol Med 40:237\u2013245","journal-title":"Exp Mol Med"},{"key":"2674_CR31","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/1529-0131(200109)44:9<2176::AID-ART371>3.0.CO;2-4","volume":"44","author":"Y Katz","year":"2001","unstructured":"Katz Y, Nadiv O, Beer Y (2001) Interleukin-17 enhances tumor necrosis factor \u03b1-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts. Arthritis Rheum 44:2176\u20132184","journal-title":"Arthritis Rheum"},{"key":"2674_CR32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2005.12.009","volume":"33","author":"L Irena","year":"2006","unstructured":"Irena L, Daphna P, David L et al (2006) The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 33:106\u2013110","journal-title":"Cytokine"},{"key":"2674_CR33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2003.014738","volume":"63","author":"MC Kraan","year":"2004","unstructured":"Kraan MC, Smeets TJ, van Loon MJ et al (2004) Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 63:1056\u20131061","journal-title":"Ann Rheum Dis"},{"key":"2674_CR34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","volume":"40","author":"A Masataka","year":"2007","unstructured":"Masataka A, Hiroshi T (2007) The molecular understanding of osteoclast differentiation. Bone 40:251\u2013264","journal-title":"Bone"},{"key":"2674_CR35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.molmed.2008.04.001","volume":"14","author":"H Sonja","year":"2008","unstructured":"Sonja H, Gerhard K, Georg S (2008) Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 14:245\u2013253","journal-title":"Trends Mol Med"},{"key":"2674_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","volume":"12","author":"T Wada","year":"2006","unstructured":"Wada T, Nakashima T, Hiroshi N et al (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17\u201325","journal-title":"Trends Mol Med"},{"key":"2674_CR37","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","volume":"32","author":"G Nicola","year":"2004","unstructured":"Nicola G, Simona C, Vittorio R (2004) New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-\u03baB ligand (RANKL). Exp Hematol 32:685\u2013691","journal-title":"Exp Hematol"},{"key":"2674_CR38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jcb.22326","volume":"108","author":"Y Toru","year":"2009","unstructured":"Toru Y, Yuki N, Naomi I et al (2009) IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-a antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 108:947\u2013955","journal-title":"J Cell Biochem"},{"key":"2674_CR39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.biochi.2010.10.001","volume":"93","author":"F Zhang","year":"2011","unstructured":"Zhang F, Tanaka H, Kawato T et al (2011) Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie 93:296\u2013305","journal-title":"Biochimie"},{"key":"2674_CR40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2007.09.011","volume":"117","author":"JH Ju","year":"2008","unstructured":"Ju JH, ChoML JhunJY et al (2008) Oral administration of type-II collagen suppresses IL-17 associated RANKL expression of CD4+T cells in collagen-induced arthritis. Immunol Lett 117:16\u201325","journal-title":"Immunol Lett"},{"key":"2674_CR41","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.21021","volume":"52","author":"G Schett","year":"2005","unstructured":"Schett G, Middleton S, Bolon B (2005) Additive bone protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 52:1604\u20131611","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2674-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-013-2674-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-013-2674-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T13:25:51Z","timestamp":1562592351000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-013-2674-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,19]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2674"],"URL":"https:\/\/doi.org\/10.1007\/s00296-013-2674-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,19]]}}}